Ken André OLAUSSEN
机构: Maître de conférences (Associate Professor), University of Paris Sud
每年引用次数
引用次数
引用: 7,036
H-指数: 35
I10-指数 : 53
出版物: 110
ERCC1 et cancer pulmonaire
D. Planchard , K.-A. Olaussen , J.-C. Soria
Revue Des Maladies Respiratoires 27 ( 4) 387 -394
2
2010
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc , Julien Adam , Emilie Louvet , Tony Sourisseau
ESMO open 3 ( 1)
31
2018
Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance
Tony Sourisseau , Carole Helissey , Céline Lefebvre , Florence Ponsonnailles
Cell Cycle 15 ( 2) 295 -302
24
2016
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on NSCLC carcinoma cell lines
Frederic Commo , Ken A Olaussen , Maximilien Tailler , Ludovic Lacroix
JOURNAL OF THORACIC ONCOLOGY 4 ( 9) S595 -S596
2009
Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study
Francesco Facchinetti , Rastislav Bahleda , Antoine Hollebecque , Yohann Loriot
Cancer Research 79 ( 13_Supplement) 318 -318
1
2019
Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches
Jeanne Chen , Floriane Braye , Francesco Facchinetti , Ludovic Lacroix
Cancer Research 80 ( 16_Supplement) 1867 -1867
2020
Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer
Gonzalo Recondo , Laura Mezquita , David Planchard , Anas Gazzah
Cancer Research 79 ( 13_Supplement) 311 -311
2019
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
Francesco Facchinetti , Antoine Hollebecque , Floriane Braye , Damien Vasseur
Cancer discovery 13 ( 9) 1998 -2011
9
2023
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer
International Adjuvant Lung Trial-Bio investigators , Nermine S Kamal , Jean-Charles Soria , Jean Mendiboure
Clinical cancer research 16 ( 4) 1206 -1215
117
2010
Docetaxel-platinum-fluorouracil (TPF) induction chemotherapy increases PD-L1 positivity and CD8+/FOXP3+ immune infiltrates in advanced head and neck squamous cell carcinoma (HNSCC)
Charlotte Leduc , Julien Adam , Emilie Louvet , Marine Bernard
Cancer Research 76 ( 14_Supplement) 5006 -5006
2016
ERCC1 gene copy number variations in resected non-small cell lung cancer
Luc Friboulet , Ken A Olaussen , Alexander Valent , Ximing Tang
Cancer Research 72 ( 8_Supplement) 3098 -3098
2012
DNA repair mechanisms to tailor therapy in NSCLC
Ken A Olaussen , Jean-Charles Soria
JOURNAL OF THORACIC ONCOLOGY 4 ( 9) S42 -S43
2009
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Ken A Olaussen , Ariane Dunant , Pierre Fouret , Elisabeth Brambilla
The New England Journal of Medicine 355 ( 10) 983 -991
1,466
2006
Characterization of TKI-induced drug-tolerant persister cells from a patient-derived cell line
Floriane Brayé , Francesco Facchinetti , Helena Gerber , Juliette Juigné
Cancer Research 83 ( 7_Supplement) 425 -425
2023
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Ken A Olaussen , Julien Adam , Elsa Vanhecke , Philippe Vielh
Lung Cancer 80 ( 2) 216 -222
30
2013
PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors
Judith Michels , Ilio Vitale , Lorenzo Galluzzi , Oliver Kepp
Cancer Research 72 ( 8_Supplement) 3115 -3115
2012
ERCC1-202 isoform is responsible for all known functions of ERCC1.
Luc Friboulet , Ken André Olaussen , Florence Ponsonnailles , Annabelle Stoclin
Cancer Research 73 ( 8_Supplement) 630 -630
1
2013
Telomere length is associated with survival in uterine sarcoma (US)
Marie-Anne Marrière , Luc Morat , Ken André Olaussen , Patricia Pautier
Cancer Research 64 ( 7_Supplement) 620 -621
2004
Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC.
Ken Andre Olaussen , Jean-Charles Soria , Luc Morat , Antoine Martin
Anticancer Research 23 4885 -4890
16
2003
PARP inhibitors: an interesting pathway also for non-small cell lung cancer?
Matteo Giaj Levra , Ken Andre Olaussen , Silvia Novello , Jean-Charles Soria
Current pharmaceutical design 20 ( 24) 3875 -3882
18
2014